• Citer

Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.

par Mathieu, Chantal;Wych, Julie;Hendriks, Emile AEJ;Van Ryckeghem, Lisa;Tree, Timothy;Chmura, Piotr;Möller, Christopher;Casteels, Kristina;Danne, Thomas;Reschke, Felix;Šmigoc Schweiger, Darja;Battelino, Tadej;Johannesen, Jesper;Rami-Merhar, Birgit;Pieber, Thomas;De Block, Christophe;Evans, Mark;Hilbrands, Robert;Bosi, Emanuele;Willemsen, Ruben H;Basu, Supriyo;Pulkkinen, Mari Anne;Knip, Mikael;Cnop, Miriam ;Nitsche, Almut;Schulte, Anke M;Niemöller, Elisabeth;Peakman, Mark;Wilhelm-Benartzi, Charlotte;Gillespie, David;Overbergh, Lut;Mander, Adrian Paul;Marcovecchio, Maria Loredana;INNODIA,
Référence Lancet, 406, 10510, page (1375-1388)
Publication Publié, 2025-09-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Type 1 diabetes remains an important health-care problem, with no disease-modifying therapies available in people with recent-onset, clinical type 1 diabetes. Adaptive trial designs, allowing faster evaluation of treatment modalities, remain underexplored in this stage of the disease. We aimed to identify the minimum effective dose of antithymocyte globulin (ATG) in people aged 5-25 years with recent-onset, clinical type 1 diabetes.